A double-blind, randomized, parallel-group study to compare the efficacy and safety of TAK-491 with valsartan in subjects with essential hypertension.

Trial Profile

A double-blind, randomized, parallel-group study to compare the efficacy and safety of TAK-491 with valsartan in subjects with essential hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 01 Jul 2011 Results published in the Journal of Clinical Hypertension (Greenwich).
    • 22 Jun 2010 Results reported at ESH in June 2010, according to a Takeda media release.
    • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top